delta-inulin |
|
Vaxjo ID |
236 |
|
Vaccine Adjuvant Name |
delta-inulin |
|
Adjuvant VO ID |
VO_0005723
|
|
Description |
A particulate polysaccharide adjuvant derived from inulin, enhances both humoral and cellular immune responses |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
NCT04453852 (for COVAX-19) |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
Advax, a delta inulin-derived microparticle, has been developed as an adjuvant for several vaccines. |
|
Structure |
Comprised of 2 μm particles; resistant to degradation in lysosomes |
|
Appearance |
Administered as a suspension; fluorescein-conjugated Advax was used in study |
|
Storage |
Stored at −80°C for research |
|
Preparation |
Used as 1 mg/dose in PBS, either alone or with antigen (CysVac2) via intrapulmonary delivery |
|
Dosage |
1 mg Advax + 3 µg CysVac2 per dose, intratracheally in mice |
|
Function |
Mucosal vaccine delivery is an attractive option as it directly targets the site of infection; however, preclinical development has been hindered by a lack of suitable mucosal adjuvants and a limited understanding of their immune effects in the lung environment. Herein, we define the early immune events following the intrapulmonary delivery of a vaccine incorporating the adjuvant delta-inulin. |
|
Safety |
Good safety profile; transient immune cell recruitment and cytokine burst with no prolonged inflammation; no eosinophilic or Th2 bias seen |
| References |
Ferrell et al., 2021: Ferrell KC, Stewart EL, Counoupas C, Ashhurst TM, Britton WJ, Petrovsky N, Triccas JA. Intrapulmonary vaccination with delta-inulin adjuvant stimulates non-polarised chemotactic signalling and diverse cellular interaction. Mucosal immunology. 2021; 14(3); 762-773. [PubMed: 33542494].
|
